Thrombosis was considered as a separate safety event for follow reasons: first, cancer patients undergoing chemotherapy are at a high risk of thrombosis [17]; second, the proportion of platelets > 400 × 109/L in the experimental group is higher, and an elevated platelet count is also a risk factor for thrombosis [18]; third, TPO-RAs have been reported to increase the risk of thrombosis, but the mechanism remains unclear [19]. The gene discussed is TPO; the disease is deep vein thrombosis.